Legend Biotech (LEGN) Stock Hits New Lows: Oversold CAR-T Leader or Long-Term Opportunity?
As of December 9, 2025, shares of Legend Biotech Corporation (NASDAQ: LEGN) are under heavy pressure even as the company posts strong growth from its flagship CAR-T therapy, CARVYKTI. Here’s a deep dive into the latest news, forecasts, analyst calls
